JO3658B1 - بروتينات اندماج - Google Patents

بروتينات اندماج

Info

Publication number
JO3658B1
JO3658B1 JOP/2016/0076A JOP20160076A JO3658B1 JO 3658 B1 JO3658 B1 JO 3658B1 JO P20160076 A JOP20160076 A JO P20160076A JO 3658 B1 JO3658 B1 JO 3658B1
Authority
JO
Jordan
Prior art keywords
span
fusion proteins
dir
ltr
present
Prior art date
Application number
JOP/2016/0076A
Other languages
English (en)
Inventor
Bruce Baldwin David
Duane Dickinson Craig
Alan Lazar Gregory
Wesley Day Johnathan
Ihor Korytko Andrew
Michael Beals John
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55953435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3658(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3658B1 publication Critical patent/JO3658B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

يتعلق الاختراع الحالي ببروتينات اندماج تشتمل على مساعد مستقبل إنسولين مدمج مع منطقة<span dir="LTR">Fc </span> <span dir="LTR">IgG</span> بشرية من خلال استخدام رابط ببتيد، واستخدام بروتينات الاندماج المذكورة في معالجة مرض السكري. يكون لبروتينات الاندماج للاختراع الحالي خاصية ممتدة المفعول وتكون نافعة في توفير تحكم في مستوى الجلوكوز القاعدة لفترة زمنية ممتدة<span dir="LTR">.</span>
JOP/2016/0076A 2015-05-07 2016-04-21 بروتينات اندماج JO3658B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562158079P 2015-05-07 2015-05-07

Publications (1)

Publication Number Publication Date
JO3658B1 true JO3658B1 (ar) 2020-08-27

Family

ID=55953435

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0076A JO3658B1 (ar) 2015-05-07 2016-04-21 بروتينات اندماج

Country Status (40)

Country Link
US (5) US9855318B2 (ar)
EP (1) EP3292141B1 (ar)
JP (1) JP6591562B2 (ar)
KR (1) KR102059736B1 (ar)
CN (1) CN107531806B (ar)
AR (1) AR105616A1 (ar)
AU (1) AU2016257659B2 (ar)
CA (1) CA2981102A1 (ar)
CL (1) CL2017002761A1 (ar)
CO (1) CO2017011301A2 (ar)
CR (1) CR20170469A (ar)
CY (1) CY1122929T1 (ar)
DK (1) DK3292141T3 (ar)
DO (1) DOP2017000258A (ar)
EA (1) EA039770B1 (ar)
EC (1) ECSP17073650A (ar)
ES (1) ES2799099T3 (ar)
HR (1) HRP20200503T1 (ar)
IL (1) IL254965B (ar)
JO (1) JO3658B1 (ar)
LT (1) LT3292141T (ar)
MA (1) MA42037B1 (ar)
MD (1) MD3292141T2 (ar)
ME (1) ME03709B (ar)
MX (1) MX388594B (ar)
MY (1) MY183025A (ar)
NZ (1) NZ736470A (ar)
PE (1) PE20180507A1 (ar)
PH (1) PH12017502025A1 (ar)
PL (1) PL3292141T3 (ar)
PT (1) PT3292141T (ar)
RS (1) RS60044B1 (ar)
SG (1) SG11201708194WA (ar)
SI (1) SI3292141T1 (ar)
SV (1) SV2017005548A (ar)
TN (1) TN2018000059A1 (ar)
TW (1) TWI656132B (ar)
UA (1) UA122146C2 (ar)
WO (1) WO2016178905A1 (ar)
ZA (1) ZA201706334B (ar)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
RU2719856C1 (ru) 2016-07-27 2020-04-23 Хьюлетт-Паккард Дивелопмент Компани, Л.П. Горизонтальный интерфейс для картриджа с запасом текучей среды, имеющего цифровой датчик уровня текучей среды
AU2017371217B2 (en) * 2016-12-09 2020-03-19 Akston Biosciences Corporation Insulin-Fc fusions and methods of use
TR201703622A1 (tr) * 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
EP3743088B1 (en) * 2018-01-26 2022-10-12 F. Hoffmann-La Roche AG Il-22 fc compositions and methods of use
EP3810640A1 (en) 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
CN113038964B (zh) * 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
WO2020074544A1 (en) 2018-10-10 2020-04-16 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use
MX2021005593A (es) 2018-11-20 2021-08-11 Univ Washington Miméticos de interleucina dividida y sus usos.
CN113613629A (zh) * 2019-03-15 2021-11-05 伊莱利利公司 防腐的制剂
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
DK4073098T5 (da) * 2019-12-19 2024-07-22 Akston Biosciences Corp Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP4121449A2 (en) 2020-03-16 2023-01-25 Neoleukin Therapeutics, Inc. Interleukin-2 receptor beta (il-2rb) binding polypeptides
EP4132964A2 (en) 2020-04-07 2023-02-15 Neoleukin Therapeutics, Inc. De novo protein decoys of angiotensin-converting enzyme 2 (ace2)
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11213581B2 (en) 2020-04-10 2022-01-04 Akston Biosciences Corporation Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US20230272030A1 (en) * 2020-07-24 2023-08-31 Jiangsu Gensciences Inc. Insulin-fc fusion protein and application thereof
MX2023005197A (es) * 2020-11-06 2023-05-16 Amgen Inc Dominio de union a antigeno con tasa de recorte reducida.
AU2021400816B2 (en) * 2020-12-14 2025-07-10 Eli Lilly And Company Methods of treating diabetes
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
WO2023044318A2 (en) 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
TWI871539B (zh) * 2021-11-15 2025-02-01 美商美國禮來大藥廠 可保存之調配物
TW202342552A (zh) * 2022-03-16 2023-11-01 大陸商北京拓界生物醫藥科技有限公司 人胰島素類似物、其融合蛋白及醫藥用途
AR129357A1 (es) 2022-05-18 2024-08-14 Protomer Tech Inc Compuestos aromáticos que contienen boro y análogos de insulina relacionados
EP4543909A1 (en) 2022-06-23 2025-04-30 Sanofi Single chain insulins and fc conjugates thereof
WO2024137820A1 (en) * 2022-12-20 2024-06-27 The Board Of Trustees Of The Leland Stanford Junior University Insulin receptor antagonist
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白
EP4706053A1 (en) 2023-05-03 2026-03-11 Eli Lilly and Company Methods and systems for managing diabetes
WO2025059010A1 (en) 2023-09-11 2025-03-20 Eli Lilly And Company Methods and systems for managing diabetes
WO2025061146A1 (zh) * 2023-09-20 2025-03-27 上海迈晋生物医药科技有限公司 一种人胰岛素类似物融合蛋白的药物组合物及其医药用途
WO2025080923A1 (en) 2023-10-13 2025-04-17 Eli Lilly And Company Insulin-fc fusion proteins
US12454565B2 (en) 2024-03-21 2025-10-28 Akston Biosciences Corporation PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
UA93662C2 (uk) 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
BR0215029A (pt) 2001-12-20 2005-12-20 Lilly Co Eli Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
EA008831B1 (ru) 2003-06-12 2007-08-31 Эли Лилли Энд Компани Слитые белки аналогов glp-1
DE60333600D1 (de) 2003-10-02 2010-09-09 Zeiss Carl Smt Ag Projektionsobjektiv für die halbleiter-lithographie
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
US20090069216A1 (en) 2006-02-21 2009-03-12 Novo Nordisk A/S Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
EP1996709A2 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
US20090069215A1 (en) 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
EP2404934A1 (en) 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
CA2687377C (en) * 2007-05-30 2013-05-14 Genexine Co., Ltd. Immunoglobulin fusion proteins
US20100196405A1 (en) 2007-07-10 2010-08-05 Kingman Ng GLP-1 Fc FUSION PROTEIN FORMULATION
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
MX2010009850A (es) * 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
CN102065885A (zh) 2008-04-22 2011-05-18 卡斯西部储备大学 同种型特异性的胰岛素类似物
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
EP2300501B1 (en) 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
MX2013009280A (es) 2011-02-09 2013-09-06 Glaxosmithkline Llc Formulaciones liofilizadas.
CN102718870B (zh) * 2011-05-24 2014-04-30 马鞍山中美德康生物科技有限公司 一种胰岛素生物增敏剂及其应用
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
MX2015005662A (es) 2012-11-05 2015-08-20 Univ Case Western Reserve Analogos de insulina de una sola cadena de larga accion.
SG11201505615PA (en) 2013-02-26 2015-09-29 Hanmi Pharm Ind Co Ltd Site-specific insulin conjugate
JP6525951B2 (ja) * 2013-03-14 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アペリン融合タンパク質およびその使用
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
US10253082B2 (en) 2014-01-20 2019-04-09 Hanmi Pharm. Co., Ltd Long-acting insulin and use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
CN107108716A (zh) 2014-10-06 2017-08-29 卡斯西部储备大学 双相性单链胰岛素类似物
SG10201809457YA (en) 2014-11-21 2018-11-29 Merck Sharp & Dohme Insulin receptor partial agonists
CN107810202A (zh) 2015-02-17 2018-03-16 韩美药品株式会社 长效胰岛素或胰岛素类似物复合物
CN110134210A (zh) 2019-04-16 2019-08-16 深圳市国鑫恒宇科技有限公司 一种服务器一体机的温度控制方法、系统、装置及存储介质

Also Published As

Publication number Publication date
HRP20200503T1 (hr) 2020-06-26
US20250032588A1 (en) 2025-01-30
IL254965B (en) 2021-03-25
ES2799099T3 (es) 2020-12-14
PT3292141T (pt) 2020-04-22
TW201712029A (zh) 2017-04-01
US20220211818A1 (en) 2022-07-07
CR20170469A (es) 2017-11-14
US11253574B2 (en) 2022-02-22
US9855318B2 (en) 2018-01-02
PH12017502025B1 (en) 2018-04-02
MD3292141T2 (ro) 2020-07-31
AU2016257659A1 (en) 2017-10-12
ECSP17073650A (es) 2018-02-28
MY183025A (en) 2021-02-07
LT3292141T (lt) 2020-03-25
EP3292141A1 (en) 2018-03-14
TN2018000059A1 (en) 2019-07-08
US20180177851A1 (en) 2018-06-28
HK1244019A1 (en) 2018-07-27
EA201792199A1 (ru) 2018-03-30
DK3292141T3 (da) 2020-04-20
CL2017002761A1 (es) 2018-05-18
SV2017005548A (es) 2018-04-24
EA039770B1 (ru) 2022-03-11
AR105616A1 (es) 2017-10-25
MA42037B1 (fr) 2020-03-31
PH12017502025A1 (en) 2018-04-02
US12059452B2 (en) 2024-08-13
EP3292141B1 (en) 2020-02-12
US20160324932A1 (en) 2016-11-10
KR102059736B1 (ko) 2019-12-26
ME03709B (me) 2021-01-20
CY1122929T1 (el) 2021-10-29
RS60044B1 (sr) 2020-04-30
CO2017011301A2 (es) 2018-03-20
TWI656132B (zh) 2019-04-11
CN107531806B (zh) 2022-06-07
JP6591562B2 (ja) 2019-10-16
DOP2017000258A (es) 2017-12-31
NZ736470A (en) 2019-04-26
KR20170134614A (ko) 2017-12-06
CN107531806A (zh) 2018-01-02
MX2017014284A (es) 2018-03-23
ZA201706334B (en) 2020-01-29
JP2018515088A (ja) 2018-06-14
PL3292141T3 (pl) 2020-06-29
CA2981102A1 (en) 2016-11-10
PE20180507A1 (es) 2018-03-09
IL254965A0 (en) 2017-12-31
UA122146C2 (uk) 2020-09-25
WO2016178905A1 (en) 2016-11-10
US10709766B2 (en) 2020-07-14
MX388594B (es) 2025-03-20
SI3292141T1 (sl) 2020-04-30
SG11201708194WA (en) 2017-11-29
US20200390865A1 (en) 2020-12-17
AU2016257659B2 (en) 2018-08-09
BR112017020502A2 (pt) 2018-07-03

Similar Documents

Publication Publication Date Title
JO3658B1 (ar) بروتينات اندماج
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
EP3733716A4 (en) DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE
GEAP202114720A (en) Constructs having a sirp-alpha domain or variant thereof
MX2019013023A (es) Proteina de fusion con receptor tgf-?, y uso farmaceutico de la misma.
MX360295B (es) Proteinas de fusion del ligando de ox40 (ox40l) y sus usos.
TW201613958A (en) MIC-1 fusion proteins and uses thereof
GB2564823A (en) Compositions and methods for T-cell receptors reprogramming using fusion proteins
MX2018001787A (es) Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas.
MX2021000083A (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
BR112016020377A2 (pt) proteínas fc multiméricas
BR112016023948A2 (pt) proteínas fc multiméricas
MX388977B (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso.
JOP20190097A1 (ar) الجلوبولينات المناعية واستخداماتها
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
MX2016001145A (es) Proteina de fusion terapeutica.
EA201890225A1 (ru) Слитые белки, которые связываются с fc рецепторами человека
EP3808847A4 (en) Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof
EA201991022A1 (ru) Иммуноглобулины и их применение
CY1124859T1 (el) Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение